PRTC trades 228.0% below Wall Street's consensus target of $57.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PRTC achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, PureTech Health plc (PRTC) has a Wall Street consensus price target of $57.00, based on estimates from 2 covering analysts. With the stock currently trading at $17.38, this represents a potential upside of +228.0%. The company has a market capitalization of $42M.
Analyst price targets range from a low of $44.00 to a high of $70.00, representing a 46% spread in expectations. The median target of $57.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PRTC trades at a trailing P/E of -0.4x. Analysts expect EPS to grow +72.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ROIVRoivant Sciences Ltd. | $26.1B | $36.13 | $46.75 | +29.4% | Buy | — | 15 |
 ATAIAtai Beckley Inc. | $2.7B | $7.35 | $7.69 | +4.6% | Hold | — | 8 |
 CMPSCOMPASS Pathways plc | $1.8B | $13.09 | $18.63 | +42.3% | Buy | — | 15 |
 RXRXRecursion Pharmaceuticals, Inc. | $2.0B | $3.89 | $5.30 | +36.2% | Hold | — | 10 |
 ABSIAbsci Corporation | $1.8B | $10.35 | $13.60 | +31.5% | Buy | — | 13 |
 ACADACADIA Pharmaceuticals Inc. | $3.8B | $22.18 | $33.83 | +52.5% | Buy | 35.9x | 37 |
 INVAInnoviva, Inc. | $1.5B | $20.66 | $38.00 | +83.9% | Buy | 8.4x | 10 |
 PRTAProthena Corporation plc | $436M | $8.32 | $30.00 | +260.6% | Buy | 75.6x | 28 |
 ALDXAldeyra The | $74M | $1.22 | $9.67 | +692.6% | Buy | — | 19 |
 JNJJohnson & Johnson | $651.6B | $270.68 | $286.93 | +6.0% | Buy | 23.5x | 40 |
Quick answers to the most common questions about buying PRTC stock.
The consensus Wall Street price target for PRTC is $57, representing 228.0% upside from the current price of $17.38. With 2 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
PRTC has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $57 implies 228.0% upside from current levels.
PRTC's current price is $17.38 with a consensus target of $57 (228.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $70 for PRTC, while the most conservative target is $44. The consensus of $57 represents the median expectation. These targets typically reflect 12-month expectations.
PRTC is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PRTC stock forecast based on 2 Wall Street analysts shows a consensus price target of $57, with estimates ranging from $44 (bear case) to $70 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on PRTC, with a "Buy" consensus rating and $57 price target (228.0% upside). 2 of 2 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PRTC analyst price targets range from $44 to $70, a 46% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $57 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.